Marketing-authorisation holder · Belgium

Ablynx NV

Belgium4 medicines4 countries

4 medicines in 4 countries, as authorisation holder.

Its medicines

Group structure

Part of

AblynxPharmaceutical group

Other companies in the group

Headquarters not stated1

Ablynx

Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.

Medicines

Every medicine in the registers under its name, current ones first.

4 medicines

Medicine	Substance	Country	Status	Authorised
Cablivi	Caplacizumab	EU (EMA)	Authorised	2018
CABLIVI11mg/vial · Injectable	Caplacizumab	United States	Marketed	2019
Cablivi 10 mg, Poeder en oplosmiddel voor oplossing voor injectiePoeder en oplosmiddel voor oplossing voor injectie	Caplacizumab	Netherlands	Authorised	2018
CABLIVI 10 mg10 mg · Pulb.+solv pt. sol. inj.	Caplacizumab	Romania	unknown

Sources and licences

Country	Medicines	Current	Past	Companies
European Union (EMA)	1	1	0	Companies All medicines
Netherlands	1	1	0	Companies All medicines
Romania	1	0	1	Companies All medicines
United States	1	1	0	Companies All medicines

Compiled by Prognia from the public medicine and company registers below. Logos are not used.

European Medicines Agency

Source: European Medicines Agency (EPAR data).

Licence: EMA reuse policy (source acknowledgement required)

U.S. Food and Drug Administration (Drugs@FDA, openFDA)

Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.

Licence: Public domain (U.S. Government work)

Base de données publique des médicaments (ANSM, HAS, UNCAM)

Source: BDPM (ANSM, HAS, UNCAM).

Licence: Licence Ouverte v1.0

BDPM / ANSM, HAS and UNCAM

BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained

Licence: BDPM exact Licence Ouverte v1.0 (October 2011)

BDPM / ANSM, HAS and UNCAM, France

BDPM / ANSM, HAS and UNCAM, CIS_MITM.txt, published 13/10/2026, acquired 2026-10-25T22:15:46.803459+00:00; exact facts retained, no endorsement.

Licence: BDPM exact Licence Ouverte v1.0 (October 2011)

Agenzia Italiana del Farmaco (AIFA), Italy

Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_H_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:40 GMT; acquired 2026-10-13T17:21:06.034935+00:00; native fields retained, source identifier and role projections are adaptations.

Licence: CC BY 4.0; AIFA published open-data catalog

All 12 sources

Agenzia Italiana del Farmaco (AIFA), Italy

Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.

Licence: CC BY 4.0; AIFA published open-data catalog

College ter Beoordeling van Geneesmiddelen

College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.

Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim

Ministerul Sănătății

Ministerul Sănătății, Catalogul public naţional al preţurilor, 18 iunie 2021, downloaded 2026-10-08 from data.gov.ro; CC BY 4.0; structured factual adaptation, code whitespace trimmed only where explicitly recorded.

Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)

Läkemedelsverket, Sweden

Läkemedelsverket, Sweden, Förvaringstemperatur och hållbarhet, source extract 2026-10-20, acquired 2026-10-20T20:46:08.868635+00:00. Original cells retained; structured adaptation by Prognia. No regulator endorsement.

Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)

Läkemedelsverket, Sweden

Läkemedelsverket, Sweden, Läkemedelsprodukter, source extract 2026-10-20, acquired 2026-10-20T20:45:53.483733+00:00. Original cells retained; structured adaptation by Prognia. No regulator endorsement.

Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)

U.S. Food and Drug Administration

FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.

Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions

Report an error or request removal Corrections from the company itself are welcome.

Ablynx NV

Group structure

Part of

Other companies in the group

Headquarters not stated1

Medicines

Know your medicines, with the sources.

Ablynx NV

Group structure

Part of

Other companies in the group

Headquarters not stated1

Medicines

Know your medicines, with the sources.

Countries

Therapeutic areas

Top substances

Names in the registers

Sources and licences

At a glance

Work with Prognia

Belgium: more companies